Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer (TNBC) with a win in a phase 3 combination trial with MSD's PD-1 inhibitor Keytruda.

DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer. Business Wire Jun 24, 2025, 11:00:00 AM.